Bremelanotide

Drug Profile

Bremelanotide

Alternative Names: PT-141; RekyndaTM

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Arizona
  • Developer Palatin Technologies; Simons Foundations
  • Class Cyclic peptides; Erectile dysfunction therapies; Hypothalamic hormones; Melanocyte-stimulating hormones
  • Mechanism of Action Melanocortin type 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Female sexual dysfunction
  • Phase II Cognition disorders
  • No development reported Erectile dysfunction
  • Discontinued Haemorrhagic shock; Vascular disorders

Most Recent Events

  • 06 Sep 2017 Bremelanotide licensed to Shanghai Fosun Pharmaceutical in China, Taiwan, Hong Kong and Macau for Female sexual dysfunction
  • 04 Aug 2017 Drug interactions data released by AMAG Pharmaceuticals
  • 16 May 2017 AMAG Pharmaceuticals announces intention to submit a New Drug Application for Female sexual dysfunction in early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top